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ABSTRACT 
Purpose:  
To experimentally investigate the arterial wall/device compliance mismatch of four stent-
graft devices and a multi-layer flow modulator within the supra- and infra-renal locations for 
the treatment of Abdominal Aortic Aneurysms (AAA). 
Methods:  
Five devices (MFM™, Endurant II™, Excluder™, Zenith™ and Fortron™) were tested 
under physiologically flow conditions within a flow simulator system comprising of a 
patient-specific thin-walled flexible AAA perfusion model with replicated intraluminal 
thrombus (ILT), supported by the spinal column. Devices were submitted to circumferential 
force tests and implanted in the perfusion model for circumferential arterial pressure/diameter 
measurements. Parameters, including: radial resistive force, supra-/infrarenal compliance, 
pulsatile arterial energy loss (PAEL), pulse wave velocity (PWV) and waves reflection 
coefficient (Γ), were computed to characterise the device performance.    
Results:  
The Zenith™ and Endurant II™ devices had the highest radial resistive force (up to 3 N/cm), 
while the Fortron™ device had the lowest (0.11 N/cm). The compliance varied between 6.9 
to 5.1×10-4/mmHg (suprarenal), and between 4.8 to 5.4×10-4/mmHg (infrarenal). Two 
devices (Endurant II™ and Excluder™) significantly decreased the infrarenal compliance by 
13 – 26% (p<0.001). Four devices increased the PAEL by 13 – 44% (p<0.006). The PWV 
ranged from 10.9 m/s (MFM™, p=0.164) to 15.1m/s (Endurant II™, p<0.001). There was an 
increase of 8 – 238% (p<0.001) in the reflection coefficient for all devices.  
Conclusions:  
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Commercially available endovascular devices lower the aortic wall compliance after 
implatation. The MFM™ was found to be the most compliant in the surprarenal region, while 
the Fortron™ device was the most compliant in the infrarenal region.  
INTRODUCTION 
The endovascular treatment (EVAR) of abdominal aortic aneurysms (AAAs) is the 
contemporary first line therapy, with open repair reserved for those who are unfit for EVAR. 
EVAR offers clear benefits when compared to open repair, in terms of less trauma, short 
hospital stay, reduced mortality and lower morbidity. However, associated stent-graft (SG) 
fixation problems, such as endoleaks, migration and proximal neck enlargement 1,2 can affect 
the long-term success of the EVAR.3 The changes in compliance after stenting, at the 
interface between the stent and the arterial wall, represent a compliance mismatch. 
Compliance mismatch between these devices and the arterial wall may contribute to these 
reported issues. Arterial compliance is a change in vessel diameter or cross-sectional area 
triggered by a change in blood pressure. The arterial compliance, relative pulsatility, and 
pulsatile diameter are dramatically changed following the introduction of an implant SG in an 
artery, as found by Humphery4 and Tortoriello5. Therefore a device/arterial wall compliance 
mismatch can be attributed to the change in arterial compliance in the vicinity of the 
implanted stent. To date, it is unclear how stents affect the compliance of an artery, as 
compliance varies from one type of stent to another. One stent type can cause the arterial wall 
to behave rigidly, while another type may have no effect.6  
The compliance mismatch alters the haemodynamics due to the reduced compliance within 
the vicinity of the SG/arterial wall interface3,7 which may lead to increased pressure due to 
pulse wave reflections2. The reduction in arterial wall compliance influences the 
haemodynamics in terms of blood flow patterns and von Mises stress in the wall, as was 
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shown by Ene et al.8, who computationally analysed the haemodynamics in six abdominal 
aortic aneurysms under different assumptions, such as static/transient pressures, 
steady/transient flows and rigid/compliant walls.  Vernhet et al.7 and Morris et al.2 showed a 
significant decrease in compliance when using small stents in small-calibre rabbit arteries and 
a SG device within an AAA perfusion model respectively, while Pihkala et al.9 found that 
implanted stents in pig’s aortas didn’t affect aortic compliance or alter the pulse wave 
velocity (PWV). Also, in-vivo monitoring by intravascular ultrasound within coronary lesions 
shows a decrease in compliance post implantation of endovascular scaffolds.10 Changes in 
arterial compliance triggers arterial dysfunction and pathophysiology, which have a key role 
in vascular biomechanics and homeostasis.11 Vlachopoulos et al.12 found that a 1 m/s increase 
in the PWV generates a 14% increased risk of cardiovascular events, cardiovascular mortality 
and all-cause mortality. Also, an increase of 1 SD in PWV is associated with a further 
increased risk of over 40%.   
To date, little is known on the influence that commercially available devices have on the 
SG/arterial wall compliance for the treatment of AAAs. The hypothesis of this study is that 
SGs play a major role in altering the local arterial compliance after implantation. In this study 
we are investigating the mechanical behaviour of five commercially available endovascular 
devices: four SGs (Endurant IITM, FortronTM, ZenithTM, ExcluderTM) and one multilayer flow 
modulator (MFMTM) device, in order to discover if and how, the arterial compliance, is 
affected after implantation, by using an AAA perfusion model that, accurately, replicates the 
mechanical behaviour of the human aorta artery. The device/arterial wall compliance 
mismatch may be accounted for SG fixation problems such as Type I endoleaks and 
migration.  
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METHODS 
Stent-Graft and MFM Devices 
Four bifurcated SG devices and a Multilayer Flow ModulatorTM (MFMTM) device (Figure 
1B) for the treatment of AAAs were dynamically tested within the AAA perfusion model.  
The five tested devices were as follows: 
 MFMTM (Cardiatis, Belgium),   
 Endurant IITM SG (Medtronic, USA),  
 EXCLUDERTM (Gore Medical, USA),  
 ZenithTM (Cook Medical, USA),  
 FortronTM (Cordis, Sommerville, NJ). 
All SG devices (Figure 1B) have a thin walled graft covering the aneurysmal sac region, 
while the MFMTM has no graft covering along the stent structure. The MFMTM device is, also, 
bifurcated by having the lower tube half, stapled along the middle by the manufacturer, thus 
creating a bifurcation configuration with 2 tubular channels, in which two smaller MFMTM 
stents were deployed during implantation in the perfusion model as device limbs. Table 1 
summarises the devices sizes according to IFU documentation.  Based on the infrarenal 
internal/external neck sizes of the AAA, the clinicians sized the devices according to the 
manufacturer’s indication for use (IFU) and not the maximum proximal diameter.  The 
maximum proximal and distal diameters varied from (28 - 30mm) and (14 - 16mm), 
respectively. The AAA had an infrarenal neck angle of 57°, which falls within the IFU 
recommendations for four devices, but the MFMTM. The ZenithTM, ExcluderTM and FortronTM 
devices can be used if the minimum neck length is 15mm and the infrarenal neck angle is 
<60°, while Endurant IITM can be used if the infrarenal neck angle is <75°, for the same 
minimum neck length of 15mm. The IFU of the MFMTM does not specify a threshold for the 
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infrarenal neck angulation. The MFMTM is the last device to collapse in a neck angulation 
situation greater than 60°, judging by its observed bending behaviour, due to its stent design. 
The different lengths resulted when selecting the devices used from the ones that we had 
access to. The devices were deployed inside the AAA perfusion model, as shown in Figure 2 
(A & B), and neck outer diameters were measured at rest without any pressurization, as 
shown in Table 2, in order to ensure that the experiment started at similar levels of neck 
dilatation. The measurements were focused on the proximal neck of the aneurysm without 
being influenced by the length of each device. 
Circumferential force test rig setup   
The chronic outward force is a measure of the force the stent exerts on the artery, as it tries to 
expand to its nominal diameter during vessel expansion. The radial resistive force is a 
measure of the force the stent exerts, as it resists circumferential compression by constriction 
of the artery. Both parameters depend on the state of compression. The terms chronic outward 
force and radial resistive force were coined by Duerig et al.13 to better describe the 
circumferential forces of self-expanding stents.  
Chronic outward and radial resistive circumferential forces were measured with the use of a 
high strength, low friction, 10mm wide and 0.2mm thickness, double strip material 
(DuPont™ Tyvek® paper with polyester / polyethylene laminated film), that was looped 
around the proximal end of the SG devices, and threaded through a narrow gap between two 
rollers, of the circumferential force test rig (Figure 1A), similar to the tests conducted by 
Duda et al.14 One end of the strip was attached to a fixed base, while the other end was 
attached to the clamp of a tensile tester machine (Instron 5544, UK), equipped with 10N 
static load cell. 
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The SGs were mounted on a horizontal bar support, aligned with the material loop, in order to 
maintain their position during testing (Figures 1B). The SGs were tested for 10 cycles at an 
extension rate of 190 mm/min. All six SG devices were compressed circumferentially, by a 
maximum of 20% reduction in the circumferential length. The reduction in diameter was 
given by the following formula: 
Diameter ratio = 
D
Cd

1     (1) 
where 
 Cd is the circumferential displacement, 
 D is the maximum proximal diameter of the device. 
Devices were preheated in an oven at 45°C for 10 min, to ensure full stent expansion before 
testing. The test started with the stent-grafts expanded to the maximum proximal diameter 
state. All devices were crimped to 80% of the initial diameter and then unloaded to the 
nominal outer diameter, forming a cycle as shown in Figure 3. 
Patient-specific AAA perfusion model fabrication 
A patient-specific thin-walled flexible AAA perfusion model with intraluminal thrombus 
(ILT), and the inclusion of renal and common iliac arteries was fabricated from translucent 
silicone elastomers (Figures 2 A&B) by injection moulding technique as previously described 
for idealised cases.15,16 This AAA perfusion model was based on a 72-year old patient, with 
the 3-dimensional geometry segmented within the commercially available image 
reconstruction software package Mimics® 16.0 (Materialise, Belgium). The AAA had a 
conical shaped proximal neck with constant internal diameters cranial of 23mm and caudal of 
27mm on overall circumferences, neck length of 48mm and infrarenal neck angulation of 57º.  
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The maximum aneurysm outer diameter was 65mm, iliac bifurcation inner diameter was 
33mm and the left/right common iliac inner diameters were 13mm. The arterial wall was 
replicated by Elastosil 4641 silicone (Wacker Chemie AG, Germany) with 5% silicone fluid 
(Dow Corning, UK) by weight and the ILT was replicated by Elastosil 4600 (Wacker Chemie 
AG, Germany) silicone with 25% silicone fluid (Dow Corning, UK) by weight. Due to poor 
resolution of the CT images the aortic wall thickness couldn’t be measured and reconstructed. 
Therefore, we assumed aortic wall thickness to be constant with the value of 2mm.  The 
Young’s Modulus for the silicone wall and ILT was 1.2 and 0.2MPa, respectively, as tested 
on a uniaxial tensile testing machine (Instron 5544, UK). These elastic properties were within 
previous reported tensile testing values for the abdominal aortic wall (1 to 6MPa)17  and ILT 
(0.05 to 0.27MPa)18 tissues.  The spinal column model (Figures 2 A&B) was rapid 
prototyped by a 3D printer (Stratasys Prodigy Plus, Stratasys, U.S.A) and supported the AAA 
model.  
Flow simulator system  
Blood was replicated with 56% deionised water and 44% glycerine (Univar Ltd., West 
Yorkshire, UK) that had a dynamic viscosity of 0.0035 Pa∙s at 37°C as found from a digital 
cone and plate viscometer (DV-II +PRO, Brookfield, USA) and a density of 1055kg/m3 
found by a 50ml burette and weighing scales. The required temperature of 37°C was 
controlled by a heating unit (Julabo Ltd., UK), with constant fluid stirring.  
A custom-built flow simulator (Figure 2C) replicated the aortic flowrate and pressure 
waveforms (Figure 2 D & E)19 by a programmable linear actuator (Aerotech, UK). An 
ultrasonic flow meter (TS410 plug-in module, Transonic, US) and flowsensor (25PXN Inline 
flow sensor, Transonic, US) recorded the flowrates.  22 and 28% of the inlet flowrate 
travelled through each renal and common iliac arteries respectively.19 A distal compliance 
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chamber and outlet valves controlled the pressure within physiological limits (Figure 2C). 
The pressure waveform was recorded using a 3F pressure catheter (Scisense Inc., Canada), 
positioned at the current site of measurement, along the imaginary centreline of each device, 
according to the measurement specified locations: infrarenal/suprarenal. The average 
difference between the supraceliac input (230ml/s) and measured (220.8ml/s) peak flowrate 
and pressure (input = 119mmHg and output = 114mmHg)  were less than 5%, as shown in 
Figures 2 D&E. 
The change in diameter (∆D) was measured by a 4 Mega Pixel CCD camera (Dalsa 4M30, 
Dalsa Corporation) with attached Schneider Enlarger lens (aperture F 2.8) and a frame rate of 
30 frames per second. An automatic edge detection tool (IMAQ software, National 
Instruments, UK) identified the outer edges of the perfusion model. The ∆P-∆D curve found 
by Sonesson et al.20 (Figure 2F) describing the infrarenal stiffness behaviour of the arterial 
wall, for a 69-year old age group, was used to validate the reproducibility of the human aortic 
wall behaviour within the AAA perfusion model. Pressure and change in diameter (ΔP - ∆D) 
measurements were taken at the suprarenal and infrarenal locations, 30mm above and below 
the renal arteries, prior to stenting (Figures 2 G&H). The ∆P-∆D supra- and infrarenal curves 
for the AAA perfusion model are shown in Figures 2 I&J. There was very good agreement 
between the replicated perfusion model’s behaviour with the in-vivo AAAs.  
The compliance (C)21 of the non-stented and stented AAA perfusion models were calculated 
by the following formula.  
)P(P
)A(A
A
1
C  
diassys
diassys
sys 

      (2) 
Where, the pressure (P) and area (A) were based on the systole and diastole values of the 
cardiac cycle. The AAA perfusion model had a median compliance variation of 5.4 – 7.1x10-
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4/mmHg. These results agreed with the non-invasive ultrasonic arterial compliance 
measurements for the native aorta found by Vorp et al.21 (5.1 – 19.0x10-4/mmHg),  
All statistical comparisons were generated within the Minitab® 16.2.0 statistical software 
(State college, PA, USA) by employing the Mann-Whitney non-parametric confidence 
interval (CI) testing method. All comparisons were conducted for 20 pulse cycles at the 95% 
CI.  
In order to compare and validate the results with other studies from the literature, the 
following derived parameters were calculated: pulsatile arterial energy loss (PAEL), pulse 
wave velocity (PWV) and wave reflection coefficient (Γ).  
Pulsatile Arterial Energy Loss (PAEL) 
The ∆P-∆D curve of the AAA perfusion model exhibits a hysteresis effect similar to the in-
vivo measurements of Sonesson et al.20 and Stefanadis et al.22 This area within the aortic loop 
represents the pulsatile arterial energy loss22 (PAEL).  The calculated energy loss for the 
unstented AAA perfusion model, at the suprarenal location, was 3.5mmmmHg. This was 
within the descending aortic range of 3.16 to 14.10mmmmHg.22 
Pulse wave velocity (PWV) 
The PWV was measured by monitoring the pressures and diameters at the systolic and 
diastolic phases. This data was used to estimate the local PWV by applying Equation (3)23, as 
shown in Table 2 at the infrarenal location.  
PWV = 
ΔA
ΔPA

     (3) 
 Where,  
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 A is the diastolic cross-sectional area, 
 ∆A is the difference between systolic and diastolic areas, 
 ∆P is the difference between systolic and diastolic pressures, 
   is the density of the fluid.  
Wave reflections 
The wave reflections generated within the infrarenal aortic artery, before and after stenting, 
were computed by Equation 419 (Table 2).  This equation calculates the proportion of the 
pressure waveform being reflected, and is given by the reflection coefficient (Γ),  
Γ
S
S
U
U
S
S
U
U
c
A
c
A
c
A
c
A


       (4) 
Where 
 AU - cross-sectional area upstream from the proximal side, 
 AS - cross-sectional area at the location of the proximal side, 
cU - PVW upstream from the proximal side, 
   cS - PVW at the location of the proximal side. 
RESULTS 
Device deformation characteristics  
The curves describing circumferential loading cycles and device deformation behaviour are 
shown in Figure 3. The circumferential load was divided by the length of the stent in contact 
with the strip, and this is shown in Table 2, which presents the magnitudes of the radial 
resistive and chronic outward forces expressed in N/cm, for all five SG devices at the 
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diastolic diameter of the aorta perfusion model. The Zenith™ and Endurant II™ devices had 
the highest radial resistive force (up to 3 N/cm), while the Fortron™ device had the lowest 
magnitude of 0.11 N/cm. In the second half of the cycle, the Zenith™ devices had the highest 
chronic outward force of up to 0.68 N/cm, while the Fortron™ and MFM™ had the lowest 
magnitude of 0.03 N/cm and 0.06 N/cm, respectively. 
Arterial wall/device interface compliance  
Figures 4 & 5 show the change in pressure (ΔP) and change in diameter (ΔD) curves for the 
stented AAA perfusion model at the supra and infra renal locations, respectively.  Equation 2 
was applied to find the compliance values based on these ΔP – ΔD curves, as shown in 
Figures 4 & 5. Table 2 shows the median and interquartile range (IQR) and the % median 
value compliance variations, when compared with the unstented aortic values based on the 
95% Mann-Whitney CI test.  At the suprarenal region, all devices, except the Excluder™, 
significantly decreased the compliance by 10 – 21% (p<0.002). At the infrarenal region, two 
devices (Endurant II™ & Excluder™) significantly decreased the compliance by 9 – 11% 
(p<0.001), while the MFM™, Zenith™ and Fortron™ didn’t significantly (p<0.057) 
influence the aortic compliance. Table 3 shows the infra to suprarenal device compliance 
index, which is the ratio of the mean infrarenal compliance divided by the mean suprarenal 
compliance. This compliance index for the unstented aorta was 0.75, which may represent a 
reference for device performance characterisation. The compliance indexes for all devices 
ranged from 0.71 (Excluder™) to 0.88 (Endurant II™). The MFM™ compliance index (0.76) 
was very close to the aortic compliance index. 
At the infrarenal region, the MFM™ did not significantly alter the unstented perfusion model 
PAEL median value of 2.3 mm·mmHg (p=0.903), while the other four devices increased the 
PAEL by 13 – 44% (p<0.006), as shown in Table 2.  
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Stented perfusion model pulse wave analysis 
The PWV of the unstented infrarenal section had a median value of 10.6m/s, which was in 
agreement with the postoperative findings of Paraskevas et al.24, who clinically measured the 
mean aortic PWVs of 7.84  1.85m/s (preoperatively) and 10.08  1.57m/s (postoperatively) 
within AAA cases. The PWV ranged from 10.9 m/s (MFM™, p=0.164) to 15.1m/s (Endurant 
II™, p<0.001) (see Table 2) for all devices tested. High PWVs were recorded for the 
Endurant II™ (15.1m/s, p<0.001) and Excluder™ (14.9m/s, p<0.001) devices. The Zenith™, 
Fortron™ and MFM™ devices recorded the lowest PWV measurements, with values of 11.1 
(p<0.001), 10.8 (p=0.036) and 10.9m/s (p=0.164), respectively.  
For the unstented infrarenal perfusion model, Γ had a median value of 7.6%, due to the 
tapering vessel and decreased compliance across the suprarenal and infrarenal regions.  The Γ 
was increased by 205 - 212% (p<0.001) for the Endurant IITM and ExcluderTM devices and by 
8 - 17% (p<0.001) for the MFMTM, FortronTM and ZenithTM devices. 
DISCUSSION 
As far as the authors are aware, this is the first in-vitro study, which assessed the 
haemodynamic effects of a number of devices for the treatment of AAAs, within a patient-
specific AAA perfusion model with the inclusion of ILT and correlated these effects with 
applied device fixation forces.  Previous in-vivo studies have focused on the compliance 
mismatch of stents in small calibre arteries with one stent type stiffening the arterial wall 
while another has no effect.7,9  
The arterial wall is physiologically responsive to flow disturbances and material mismatch. 
The compliance, relative pulsatility and pulsatile diameter are dramatically changed for 
implanted stents.4,10 It is unclear how stents affect the compliance of an artery as compliance 
varies from one type of stent to another. One stent type can cause the arterial wall to behave 
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rigidly7, while another type may have no effect10. The compliance mismatch at the 
arterial/stent interface increases impedance to blood flow. This may result in decreased distal 
perfusion, increased pressure wave reflections and increased pulsatile mechanical stress at the 
interface between noncompliant stented vessels and native artery.5,25 For a complete study on 
compliance mismatch six SG types were tested. The radial force characterisation of SG 
devices within the proximal region is required to determine the fixation force that would be 
acting against the arterial wall. A low radial force can result in reduced stent fixation and 
eventual migration26, while a high radial force can lead to continued dilation leading to 
migration, Type I.27 Previous studies applied point loads on stents to assess the radial force.28 
The problem with this method is that stents do not experience point loads in vivo. Another 
approach has externally compressed29 stent/SG devices and this study found the stents/SGs to 
deform asymmetrically with hysteresis during the loading and unloading cycles. Johnston et 
al.29 concluded that no usable relationship between pressure and area reduction could be 
determined due to this asymmetrical deformation. To apply axisymmetrical loading a strip 
can be wrapped around the proximal stent and pulled via a tensile testing machine deforming 
the stent circumferentially.14 The advantage of this approach is the realistic response of the 
stent which provides quantifiable results.29 The radial resistive force is a measure of the force 
the stent exerts, as it resists circumferential compression by constriction of the artery.13 There 
was a significant amount of hysteresis associated with these circumferential loading and 
unloading curves, with the radial resistive force, considerably, larger than the chronic 
outward force. Similar findings were observed by Duda et al.14, who obtained the radial 
resistive and chronic outward circumferential forces, for four 8mm diameter uncovered self-
expanding stents. The Zenith™ and Endurant II™ devices had the highest radial resistive 
force (up to 3 N), while the Fortron™ device had the lowest magnitude of 0.11 N. In the 
second half of the cycle, the Zenith™ device had the highest chronic outward force of up to 
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0.68 N, while the Fortron™ and MFM™ had the lowest magnitude of 0.03 N and 0.06 N, 
respectively. The MFM™ had the greatest discrepancy of 14 fold between the chronic 
outward force and radial resistive force, even though these circumferential forces were one of 
the lowest recorded. The radial resistive force was greater by 3.7 to 5.3 fold, when compared 
with the chronic outward force for the other five devices.  
The patient-specific perfusion model was chosen to recreate, as close as possible, an example 
of real life geometrical constraints, in which the devices have to perform. The intraluminal 
thrombus did not affect the compliance measurements, but it was replicated as part of a 
complex AAA perfusion model. Part of the aim of this study is to predict how these devices 
may behave in real patients. Further studies may be carried out regarding the influence of 
anatomy over the device performance, where straight cylindrical models can be used for 
performance comparison.   
There was a considerable reduction in the dynamic response in the region of the proximal 
side for the ExcluderTM and Endurant IITM devices, when compared to the unstented AAA 
perfusion model, as it can be seen from Figures 5 and Table 2. This resulted in a decreased 
compliance of 18 - 23 % and 14 - 25% for the suprarenal and infrarenal regions, respectively. 
The other three devices (MFM™, Zenith™ and Fortron™) had a reduced compliance of 11 - 
14 % and 1 - 7 % for the suprarenal and infrarenal regions, respectively. These differences in 
compliance between devices may be explained by the different elastic properties of the 
fabrics: woven polyester for Endurant IITM and ePTFE for ExcluderTM. Tai et al.30, measured 
the compliance of Dacron (woven polyester) and ePTFE grafts, used for vascular 
reconstruction, and found that the Dacron has a higher compliance value (1.8 ± 1.2 per cent 
per mmHg×10-2), compared to ePTFE (1.2 ± 0.3 per cent per mmHg×10-2).  
Referring to Table 3, the vertical label (device names in bold) is read against the horizontal 
label (device names in italics).  If the percentage difference values are both positive, it shows 
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that the first data set (vertical label) was significantly greater than the second (horizontal 
label), and conversely two negative values indicate that the first data set was significantly 
lower than the second.  For example, in the suprarenal region the vertical label (Endurant 
II™) was compared to the horizontal label (MFM™). This comparison showed a negative % 
difference (-22.8, -3.9; p=0.008), which means that MFM™ is more compliant than Endurant 
II™ at the suprarenal region. The three devices with suprarenal fixation (MFM™, Zenith™ 
and Fortron™) had no significant difference in compliance at the suprarenal (p>0.508) and 
infrarenal (p>0.172) regions. At the infrarenal region, the Excluder™ device, without 
proximal stent fixation, was less compliant than MFM™ (p=0.0013) and Fortron™ (p<0.001) 
devices.  
The hysteresis effect or the pulsatile energy losses within the infrarenal region was increased 
by the presence of the SG devices (Table 2 and Figure 5). The stiffest SG devices 
(ExcluderTM and Endurant IITM) within the infrarenal region increased the pulsatile energy 
losses. The MFMTM device generated only a 0.4% increase in the infrarenal aortic energy 
loss, while having the highest pulsatile energy loss within the suprarenal region (16%) due to 
the much higher metallic content within the suprarenal region. There were two highly 
nonlinear regions occurring for a normalised cumulative P - ∆D, values of 0 - 0.2 and 0.85 - 
1, for the normalised cumulative chronic outward and normalised cumulative radial resistive 
force, respectively. These two regions occurred during maximum compression of the 
proximal stents, during the loading and unloading cycles. For the rest of the pulse cycle, 0.2 - 
1 (chronic outward force) and 0 - 0.85 (radial resistive force) a more linear relationship 
existed between the normalised cumulative force values and the normalised cumulative P - 
∆D values. These nonlinear regions may be attributed to stent and graft interactions and the 
bending of the stent material at the hinges. 
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Compliance mismatch increases impendence to blood flow by increasing the PAEL within 
the arterial wall.6 This increase in PAEL may result in decreased distal perfusion, increased 
pressure wave reflections and increased pulsatile mechanical stress at the interface between 
the noncompliant stented vessels and the native artery.5,6 The elasticity of the arterial wall is 
responsible for the existence of wave reflections. The propagating pressure or flow 
waveforms will be reflected, if the wave encounters any change in calibre along the arterial 
wall, such as, a variation in cross-sectional area or material properties as given by Equation 
4.19 This variation in arterial calibre occurred after the insertion for all five devices with 
varying degrees of severity.  Wave reflections lead to the early arrival of the pressure and 
flow waveforms reflected by the prosthetic junction. The early arrival of a reflected wave 
increases left ventricular load which affects both ventricular emptying and driving pressure 
for coronary perfusion19,31, which eventually leads to low cardiac output, impaired coronary 
perfusion, heart failure, hypertension and shock.19,32There was a maximum of 7% variation in 
the maximum proximal diameter between the five devices tested (Table 1).  Unfortunately, 
this variation was unavoidable since the preferred intended for use aortic diameters as 
documented by the manufacturers were within the aorta’s infrarenal diameter range.  This 
variation in maximum proximal diameter would further contribute to the differences in 
compliance found for all devices.  Lower percentage radial pulsations would reduce the 
relative movement between the aortic wall and stent struts and may induce endothelialisation.  
This study found differences between the devices performance in terms of the main 
parameters analysed, such as the compliance and radial forces. These differences arise mainly 
from the unique combination of material properties for the fabric and stent in each device 
(briefly described in Table 1), and partly from the stent struts configurations. Three devices 
have a Z stent design (Endurant IITM, ZenithTM and ExcluderTM), one device has a proximal 
diamond stent design (FortronTM) and one device has a braided mesh design (MFMTM). The 
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stent design of last two devices produced the smallest radial forces among all tested devices 
as showed in Table 2. This fact may suggest that similar stent designs may be suitable 
towards achieving the right balance for future devices, between compliant device behaviour 
and fixation radial force, which would prevent proximal migration without stiffening the 
arterial wall. 
The reflection coefficient measurements that offer superiority to one device over another,  
may characterise the situations of highly angulated AAA necks, as it is the case in this study, 
which hasn’t been reported yet. Therefore caution should be taken when interpreting these 
results. 
Limitation 
Two limitations to the circumferential loading test approach are the unknown: the friction 
effects and the local impingement of the stent against the roller and base. With our 
circumferential loaded test, the local impingement effects were eliminated by employing a 
combination of two rollers. The film used, DuPont™ Tyvek®, has a low coefficient of 
friction. The chronic outward force is a measure of the force the stent exerts on the artery, as 
it tries to expand to its nominal diameter during vessel expansion.  
In this study we have assessed a homogenous and isotropic silicone wall, which is in contact 
with the device wall, thus creating a composite material. We assumed material homogeneity 
and isotropy, to allow the use of Equation (2) for calculating wall compliance because the 
fabric of the SGs was not stretched after deployment, and the devices struts strain within the 
ΔP was low. The relative movement between the stent struts and the aortic wall was not 
monitored. The PAEL parameter was assessed, only at the infrarenal neck, and not at the 
devices limbs, therefore it may not provide a strong relation with a potential cardiac risk.   
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Conclusion 
 The commercially available bifurcated aortic SG devices lower the arterial wall compliance 
at the stent/arterial wall interface after implantation. The Excluder™ device was found to be 
the most compliant in the surprarenal region, as this was the only tested device with no 
suprarenal fixation stent, while the MFM™ device performed better within the infrarenal 
region. From a clinical perspective, it is desired to select devices for treating AAAs, which 
produce the minimum arterial wall stiffening, in order to prevent long-term device related 
complications. Future studies should analyse, in a similar manner, a wider range of 
commercially available SG devices to identify those that would pertain for low or zero 
complications rate. 
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Table 1: Characteristics of the five endovascular AAA devices 
Device features MFM TM Endurant II TM Excluder TM Zenith TM Fortron TM 
Intended for use aortic vessel diameter [mm]  24-28 23-25 24-26 23-24 23-27 
Maximum proximal diameter  [mm] 30 28 28.5 28 30 
Maximum distal diameter [mm] 16.0 16.0 14.5 14.0 16.0 
Device length [mm] 150 170 160 184 200 
% Degree of oversizing (IFU) 25 17 18.8 17 25 
Uncovered fixation length [mm] - 15 0 30 30 
Fixation type Radial force Radial force, Barbs Radial force, Barbs Radial force, Barbs Radial force, Barbs 
Proximal fixation location Suprarenal Renal Infrarenal Suprarenal Suprarenal 
Stent material Cobalt alloy Nitinol Nitinol Stainless steel Nitinol 
Fabric material - Woven Polyester ePTFE Woven Polyester 
Woven 
Polyester 
Measured wall thickness [mm] 0.7 0.5 0.4 0.4 0.5 
Activation type Self - expanding Self - expanding Self- expanding Self -expanding Self-expanding 
Activation temperature [°C] - >30°C >30°C - >30°C 
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Table 2. Outer diameter of the perfusion model infrarenal neck after device implantation at rest, without pressurization, Chronic outward and Radial resistive force 
measurements at the infrarenal region, Perfusion model AAA Compliance, Pulse wave velocity (PWV), Reflection coefficient (Γ) and Pulsatile Arterial Energy Loss (PAEL)  
parameter comparisons for unstented/stented sections within the supra/infrarenal perfusion model’s regions, at the 95% Mann-Whitney confidence interval. 
 
Device Neck outer diameter 
after device 
implantation [mm] 
Chronic 
outward force 
[N/cm] 
Radial 
resistive force 
[N/cm] 
Energy loss 
(hysteresis) 
[mm·mmHg] 
Pulsatile  
energy loss  
(PAEL) 
 
    Median (IQR) 
[mm mmHg] 
CI  
[% variation] 
p-value 
 
Unstented 28.00 N/A N/A N/A 2.3 (2.1, 2.5) N/A N/A 
MFM TM 28.14 0.06 0.84 0.03 3.3 (3.0, 3.4) (+48.5, +33.3) <0.001 
Endurant II TM 28.63 0.54 2.85 0.15 2.3 (2.0, 2.5) (-9.4, +7.6) 0.903 
Excluder TM 28.49 0.34 1.70 0.05 2.3 (2.0, 2.4) (+54.7, +40.5) <0.001 
Zenith TM 28.31 0.67 2.88 0.14 2.7 (2.6, 2.9) (+27.1, +10.2) <0.001 
Fortron TM 28.24 0.03 0.11 0.01 2.6 (2.3, 2.9) (+23.1, +3.6) 0.006 
        
 Perfusion AAA model wall compliance         
 Suprarenal  Infrarenal  Pulse wave velocity (PWV)  Reflection coefficient (Γ) 
 Median 
(IQR) 
[10-4/mmHg] 
CI  
[% variation] 
p-value 
 Median 
(IQR) 
[10-4/mmHg] 
CI 
[% variation] 
p-value 
 
Median (IQR) 
[m/s] 
CI 
[% variation] 
p-value 
 
Median (IQR) 
[%] 
CI 
[% variation] 
p-value 
Unstented 7.1 (6.9, 7.6) N/A N/A  5.4 (5.2, 5.7) N/A N/A  10.6 (10.4, 11.0) N/A N/A  7.6 (7.4, 7.8) N/A N/A 
Endurant II™ 5.1 (5.0, 6.1) (-16.4, -27.9) <0.001  4.8 (4.2, 5.0) (-12.4, -22.4) <0.001 
 15.1 (14.2, 15.2) (+43.5, +39.5) <0.001  23.7 (23.4, 
24.0) 
(+212.6, +207.8) <0.001 
MFM™ 6.4 (5.8, 7.3) (-5.0, -17.8) 0.002  5.4 (4.8, 6.2) (-7.4, +8.8) 0.925  10.9 (10.5, 11.0) (-3.4, +0.4) 0.164  8.2 (8.0, 8.4) (+11.0, +5.7) <0.001 
Excluder™ 6.9 (6.2, 7.7) (-8.8, +3.8) 0.675  4.9 (4.4, 4.9) (-9.7, -17.5) <0.001 
 14.9 (14.6, 15.0) (+41.4, +37.4) <0.001  23.2 (22.9, 
23.5) 
(+206.4, +201.2) <0.001 
Zenith™ 6.0 (5.7, 6.7) (-10.0, -19.2) <0.001  5.3 (4.4, 5.8) (-2.6, +14.0) 0.262  11.1 (10.9, 11.4) (+6.5, +2.7) <0.001  8.9 (8.8, 9.3) (+20.9, +15.8) <0.001 
Fortron™ 6.1 (5.7, 6.8) (-8.4, -18.5) <0.001  5.2 (5.0, 5.6) (-0.15, +8.3) 0.057  10.8 (10.6, 11.1) (+3.8, +0.3) 0.036  8.6 (8.3, 8.8) (+15.5, +11.0) <0.001 
IQR = interquartile range, CI = Confidence interval (95%), a positive sign refers to a percentage increase, while a negative sign refers to a percentage decrease, N/A means not 
applicable. 
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Table 3. Statistical comparisons for suprarenal and infrarenal AAA perfusion model wall compliance 
using the Mann-Whitney confidence interval (C.I.) method at the 95% confidence interval for all five 
device configurations. The values in the round brackets refer to the % difference between the vertical and 
horizontal labels, and device Compliance index based on the ratio of the mean infrarenal compliance to 
the mean suparenal compliance.  The mean compliance values are given in [10-4/mmHg]. 
 
 Suprarenal 
 Endurant II™ MFM™ Excluder™ Zenith™ Fortron™ 
Endurant II™ X X X X X 
MFM™ 
 (-22.8, -3.9) 
p = 0.008 
X X X X 
Excluder™ 
 (-45.5, -23.9) 
p = 0.0005 
(-24.5,-6.7) 
p = 0.002 
X X X 
Zenith™ 
 (-17.4, -0.16) 
p = 0.044 
 (-4.5, +11.9) 
p = 0.508 
(+3.3, +17.2) 
p = 0.004 
X X 
Fortron™ 
(-19.1, -2.1) 
p = 0.017 
 (-6.1, +10.3) 
p = 0.655 
 (+1.48, +15.9) 
p = 0.021 
 (-6.7, +4.6) 
p = 0.617 
X 
     
 Infrarenal 
 Endurant II™ MFM™ Excluder™ Zenith™ Fortron™ 
Endurant II™ X X X X X 
MFM™ 
(-28.3, -10.0) 
p =0.0003 
X X X X 
Excluder™ 
(-10.0, +3.3) 
p =0.218 
(+4.8, +20.7) 
p =0.0013 
X X X 
Zenith™ 
(-22.9, -4.0) 
p =0.005 
(-4.0, +13.2) 
p = 0.172 
(-19.2, +0.4) 
p = 0.060 
X X 
Fortron™ 
(-22.7, -9.1) 
p =0.0001 
(-4.6, +11.3) 
p=0.525 
(-16.2, -6.1) 
p = 0.0003 
(-10.1, +7.0) 
p = 0.903 
X 
 Device Compliance Index 
Parameter 
AAA 
perfusion 
model 
MFM TM 
Endurant II 
TM Excluder
 TM Zenith TM Fortron TM 
Suprarenal  
Compliance 
7.43 6.89 5.37 6.93 6.04 6.19 
 
Infrarenal  
Compliance 
5.55 5.21 4.72 4.92 5.25 5.22 
Index 0.75 0.76 0.88 0.71 0.87 0.84 
 
   
 
